Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 387-400

  Itzkson, Raphael ^a   Fenaux, Pierre ^b   Solary, Eric ^a  

^a INSERM   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

ASXL1 gene mutation; chronic myelomonocytic leukemia; demethylating agents; gene mutations; prognostic score

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ASXL1 PROETIN; AZACITIDINE; BCR ABL PROTEIN; COHESIN; CYTARABINE; DIOXYGENASE; DNA METHYLTRANSFERASE 3A; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN; SETBP1 PROTEIN; SRSF2 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CULTURE; CHROMOSOME 20Q; CHROMOSOME 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DNA METHYLATION; ENZYME ACTIVE SITE; EOSINOPHILIA; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPING; LEUKOCYTE COUNT; MONOCYTE; MONOCYTOSIS; NEUTROPHILIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; Y CHROMOSOME;

ASXL1 GENE MUTATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DEMETHYLATING AGENTS; GENE MUTATIONS; PROGNOSTIC SCORE;

ALLOGRAFTS; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; STEM CELL TRANSPLANTATION;

EID: 84893723557     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.006     Document Type: Review

References (98)

1. J.W. Vardiman, J. Thiele, and D.A. Arber et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 5 2009 937 951
2. G. Osca-Gelis, M. Puig-Vives, and M. Saez et al. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007 Leuk Res 36 10 2012 1262 1266
3. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 2009 223 232
4. M.L. Loh Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia Br J Haematol 152 6 2011 677 687
5. E. Such, J. Cervera, and D. Costa et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia Haematologica 96 3 2011 375 383
6. A.J. Dunbar, L.P. Gondek, and C.L. O'Keefe et al. 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies Cancer Res 68 24 2008 10349 10357
7. N. Droin, A. Jacquel, and J.B. Hendra et al. Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia Blood 115 1 2010 78 88
8. N. Droin, R. Itzykson, and P. Rameau et al. Myeloid-derived suppressive cells belonging to the leukemic clone account for immunosuppression in CMML Blood ASH Ann Meet 2010 3997
9. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 3 2009 162 174
10. E. Thanopoulou, J. Cashman, and T. Kakagianne et al. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome Blood 103 11 2004 4285 4293
11. A.M. Marcondes, A.J. Mhyre, and D.L. Stirewalt et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function Proc Natl Acad Sci U S A 105 8 2008 2865 2870
12. M.H. Raaijmakers, S. Mukherjee, and S. Guo et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 7290 2010 852 857
13. P.D. Emanuel, L.J. Bates, and R.P. Castleberry et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors Blood 77 5 1991 925 929
14. E. Padron, J.S. Painter, and S. Kunigal et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia Blood 121 25 2013 5068 5077
15. N. Cambier, A. Baruchel, and M.H. Schlageter et al. Chronic myelomonocytic leukemia: from biology to therapy Hematol Cell Ther 39 2 1997 41 48
16. H.S. Ramshaw, P.G. Bardy, and M.A. Lee et al. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo Exp Hematol 30 10 2002 1124 1131
17. R. Itzykson, O. Kosmider, and A. Renneville et al. Two distinct mechanisms contribute to granulomonocytic hyperplasia in chronic myelomonocytic leukemias (CMML) ASH Annu Meet Abstr 120 21 2012 309
18. A. Kohlmann, V. Grossmann, and H.U. Klein et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1 J Clin Oncol 28 24 2010 3858 3865
19. A. Klinakis, C. Lobry, and O. Abdel-Wahab et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia Nature 473 7346 2011 230 233
20. M. Meggendorfer, A. Roller, and T. Haferlach et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML) Blood 120 15 2012 3080 3088
21. R. Itzykson, O. Kosmider, and A. Renneville et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia J Clin Oncol 31 19 2013 2428 2436
22. F. Delhommeau, S. Dupont, and V. Della Valle et al. Mutation in TET2 in myeloid cancers N Engl J Med 360 22 2009 2289 2301
23. M. Tahiliani, K.P. Koh, and Y. Shen et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 5929 2009 930 935
24. M. Ko, Y. Huang, and A.M. Jankowska et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 7325 2010 839 843
25. O. Yildirim, R. Li, and J.H. Hung et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells Cell 147 7 2011 1498 1510
26. Q. Chen, Y. Chen, and C. Bian et al. TET2 promotes histone O-GlcNAcylation during gene transcription Nature 493 7433 2013 561 564
27. C. Perez, N. Martinez-Calle, and J.I. Martin-Subero et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia PLoS One 7 2 2012 e31605
28. J. Yamazaki, R. Taby, and A. Vasanthakumar et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia Epigenetics 7 2 2012 201 207
29. E. Pronier, C. Almire, and H. Mokrani et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors Blood 118 9 2011 2551 2555
30. K. Moran-Crusio, L. Reavie, and A. Shih et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation Cancer Cell. 20 1 2011 11 24
31. C. Quivoron, L. Couronne, and V. Della Valle et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis Cancer Cell. 20 1 2011 25 38
32. R. Itzykson, O. Kosmider, and A. Renneville et al. Clonal architecture of chronic myelomonocytic leukemias Blood 121 12 2013 2186 2198
33. M. Jan, T.M. Snyder, and M.R. Corces-Zimmerman et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia Sci Transl Med 4 149 2012 149ra18
34. L. Busque, J.P. Patel, and M.E. Figueroa et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis Nat Genet 44 11 2012 1179 1181
35. K. Yoshida, M. Sanada, and Y. Shiraishi et al. Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 7367 2011 64 69
36. T.A. Graubert, D. Shen, and L. Ding et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes Nat Genet 44 1 2012 53 57
37. R. Xiao, Y. Sun, and J.H. Ding et al. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis Mol Cell Biol 27 15 2007 5393 5402
38. R. Alexander, and J.D. Beggs Cross-talk in transcription, splicing and chromatin: who makes the first call? Biochem Soc Trans 38 5 2010 1251 1256
39. T. Ernst, A.J. Chase, and J. Score et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 8 2010 722 726
40. G. Nikoloski, S.M. Langemeijer, and R.P. Kuiper et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat Genet 42 8 2010 665 667
41. A.M. Jankowska, H. Makishima, and R.V. Tiu et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A Blood 118 14 2011 3932 3941
42. J. Score, C. Hidalgo-Curtis, and A.V. Jones et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms Blood 119 5 2012 1208 1213
43. O. Abdel-Wahab, M. Adli, and L.M. LaFave et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression Cancer Cell. 22 2 2012 180 193
44. V. Gelsi-Boyer, V. Trouplin, and J. Adelaide et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 6 2009 788 800
45. O. Abdel-Wahab, O. Kilpivaara, and J. Patel et al. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration Leukemia 24 9 2010 1656 1657
46. J.C. Scheuermann, A.G. de Ayala Alonso, and K. Oktaba et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB Nature 465 7295 2010 243 247
47. A. Dey, D. Seshasayee, and R. Noubade et al. Loss of the tumor suppressor BAP1 causes myeloid transformation Science 337 6101 2012 1541 1546
48. M.C. Kuo, D.C. Liang, and C.F. Huang et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation Leukemia 23 8 2009 1426 1431
49. R.A. Padua, B.A. Guinn, and A.I. Al-Sabah et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up Leukemia 12 6 1998 887 892
50. J.W. Tyner, H. Erickson, and M.W. Deininger et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients Blood 113 8 2009 1749 1755
51. B.S. Braun, D.A. Tuveson, and N. Kong et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder Proc Natl Acad Sci U S A 101 2 2004 597 602
52. I.T. Chan, J.L. Kutok, and I.R. Williams et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease J Clin Invest 113 4 2004 528 538
53. M.E. Van Meter, E. Diaz-Flores, and J.A. Archard et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells Blood 109 9 2007 3945 3952
54. B.S. Braun, J.A. Archard, and J.A. Van Ziffle et al. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo Blood 108 6 2006 2041 2044
55. A.J. Sabnis, L.S. Cheung, and M. Dail et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells PLoS Biol 7 3 2009 e59
56. C. Ricci, E. Fermo, and S. Corti et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant Clin Cancer Res 16 8 2010 2246 2256
57. F.H. Grand, C.E. Hidalgo-Curtis, and T. Ernst et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood 113 24 2009 6182 6192
58. H. Makishima, H. Cazzolli, and H. Szpurka et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies J Clin Oncol 27 36 2009 6109 6116
59. M.H. Schmidt, and I. Dikic The Cbl interactome and its functions Nat Rev Mol Cell Biol 6 12 2005 907 918
60. M. Sanada, T. Suzuki, and L.Y. Shih et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms Nature 2009
61. C.M. Niemeyer, M.W. Kang, and D.H. Shin et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia Nat Genet 42 9 2010 794 800
62. N. Lyubynska, M.F. Gorman, and J.O. Lauchle et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice Sci Transl Med 3 76 2011 76ra27
63. J. Jelinek, Y. Oki, and V. Gharibyan et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood 106 10 2005 3370 3373
64. B.H. Lee, Z. Tothova, and R.L. Levine et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia Cancer Cell. 12 4 2007 367 380
65. K.G. Leong, and A. Karsan Recent insights into the role of Notch signaling in tumorigenesis Blood 107 6 2006 2223 2233
66. A. Kon, L.-Y. Shih, and M. Minamino et al. Recurrent mutations of multiple components of cohesin complex in myeloid neoplasms ASH Annu Meet Abstr 120 21 2012 782
67. V.C. Seitan, and M. Merkenschlager Cohesin and chromatin organisation Curr Opin Genet Dev 22 2 2012 93 100
68. R. Piazza, S. Valletta, and N. Winkelmann et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia Nat Genet 45 1 2013 18 24
69. R. Aucagne, N. Droin, and J. Paggetti et al. Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia J Clin Invest 121 6 2011 2361 2370
70. T. Braun, R. Itzykson, and A. Renneville et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial Blood 118 2011 3824 3831
71. U. Germing, A. Kundgen, and N. Gattermann Risk assessment in chronic myelomonocytic leukemia (CMML) Leuk Lymphoma 45 7 2004 1311 1318
72. P. Fenaux, R. Beuscart, and J.L. Lai et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases J Clin Oncol 6 9 1988 1417 1424
73. A. Worsley, D.G. Oscier, and J. Stevens et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival Br J Haematol 68 1 1988 17 21
74. I. Gonzalez-Medina, J. Bueno, and A. Torrequebrada et al. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center Leuk Res 26 9 2002 821 824
75. U. Germing, C. Strupp, and M. Aivado et al. New prognostic parameters for chronic myelomonocytic leukemia Blood 100 2 2002 731 732 author reply 2-3
76. F. Onida, H.M. Kantarjian, and T.L. Smith et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients Blood 99 3 2002 840 849
77. M.M. Patnaik, E. Padron, and R.R. Laborde et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes Leukemia 27 7 2013 1504 1510
78. E. Such, U. Germing, and L. Malcovati et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia Blood 121 15 2013 3005 3015
79. R.V. Tiu, L.P. Gondek, and C.L. O'Keefe et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies Blood 117 17 2011 4552 4560
80. E. Bou Samra, J. Moreaux, and F. Vacheret et al. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients Br J Haematol 157 3 2012 347 356
81. S. Schnittger, U. Bacher, and T. Alpermann et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/ myeloproliferative disorders: an analysis of 636 cases Haematologica 97 12 2012 1890 1894
82. V. Grossmann, A. Kohlmann, and C. Eder et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance Leukemia 25 5 2011 877 879
83. O. Kosmider, V. Gelsi-Boyer, and M. Ciudad et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 94 12 2009 1676 1681
84. A.M. Jankowska, H. Szpurka, and R.V. Tiu et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms Blood 113 25 2009 6403 6410
85. A.E. Smith, A.M. Mohamedali, and A. Kulasekararaj et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value Blood 116 19 2010 3923 3932
86. S.A. Kar, A. Jankowska, and H. Makishima et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia Haematologica 98 1 2013 107 113
87. V. Gelsi-Boyer, V. Trouplin, and J. Roquain et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia Br J Haematol 151 4 2010 365 375
88. H. Cheng, V.G. Kirtani, and U. Gergis Current status of allogeneic HST for chronic myelomonocytic leukemia Bone Marrow Transplant 47 4 2012 535 541
89. S. Park, M. Labopin, and I. Yakoub-Agha et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire Eur J Haematol 90 5 2013 355 364
90. P. Fenaux, P. Morel, and C. Rose et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy Br J Haematol 77 4 1991 497 501
91. P. Fenaux, J.P. Jouet, and F. Bauters Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia J Clin Oncol 5 7 1987 1129 1130
92. M. Beran, H. Kantarjian, and S. O'Brien et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 88 7 1996 2473 2479
93. P. Fenaux, A. Raza, and G.J. Mufti et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome Blood 109 10 2007 4158 4163
94. E. Wattel, A. Guerci, and B. Hecquet et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group Blood 88 7 1996 2480 2487
95. R. Costa, H. Abdulhaq, and B. Haq et al. Activity of azacitidine in chronic myelomonocytic leukemia Cancer 117 2011 2690 2696
96. L. Adès, M.A. Sekeres, and A. Wolfromm et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine Leuk Res 37 6 2013 609 613
97. A. Aribi, G. Borthakur, and F. Ravandi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia Cancer 109 4 2007 713 717
98. P.W. Wijermans, B. Ruter, and M.R. Baer et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML) Leuk Res 32 4 2008 587 591